Opinion|Videos|October 30, 2025
CNS Penetration and Efficacy of Emerging Therapies
Panelists discuss how CNS-active EGFR TKIs are improving intracranial outcomes and influencing treatment selection in NSCLC.
Advertisement
Episodes in this series
Panelists discuss how central nervous system (CNS) involvement in non–small cell lung cancer (NSCLC) poses ongoing challenges and how emerging therapies are addressing this need. They emphasize the value of agents with high CNS penetration and durable intracranial control, particularly newer tyrosine kinase inhibitors (TKIs) capable of crossing the blood-brain barrier. The discussion touches on updated NCCN guidelines recommending CNS-active options for patients with brain metastases, emphasizing how these agents improve both systemic and neurologic outcomes. This evolving understanding supports proactive CNS management as a key factor in treatment selection and patient survival.
Advertisement
Related to this article
A US modeling study found tirzepatide and semaglutide cost-effective for MASH, while resmetirom exceeded the $100,000/QALY threshold.
Expert panel discussions covered AI and community access, chronic lymphocytic leukemia, myeloma, and breast and lung cancers.
The analysis found a nonlinear association between systemic inflammation and overactive bladder, with stronger links at higher inflammation levels.
A real-world study found that adding a GLP-1 to SGLT2 inhibitor therapy was associated with lower kidney, cardiovascular, and mortality risks in CKD.
In experiments at MD Anderson, rising CD70 helps mantle cell lymphoma evade immunity; a CD70×CD3 bispecific restores T-cell killing and prolongs survival in resistant models.
Upper-extremity synovial sarcoma required more staged surgery, while lower-extremity disease carried more complications and metastases.
In the US alone, 1.1 million individuals are living with the progressive neurodegenerative movement disorder, and 90,000 are diagnosed each year.
The National Comprehensive Cancer Network update on mantle cell lymphoma puts covalent BTK inhibitors, MRD testing, and TP53 sequencing at the center of frontline care, while adding pirtobrutinib and a pair of CAR T-cell therapies for disease that progresses on a BTK inhibitor.
Advertisement
Advertisement
Trending on AJMC
1
Medicare Cap Eases Patient Costs as Negotiation Squeezes Practices
2
Access and Innovation in North Carolina’s Research Triangle
3
Biomarker-Driven Care Is Racing Ahead of the Systems Built to Support It
4
An Odyssey of Symptoms, Setbacks, Treatments, and a Cure With CAR T-Cell Therapy
5